Liposome-based immunotherapy against autoimmune diseases: Therapeutic effect on multiple sclerosis

77Citations
Citations of this article
102Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Based on the ability of apoptosis to induce immunological tolerance, liposomes were generated mimicking apoptotic cells, and they arrest autoimmunity in Type 1 diabetes. Our aim was to validate the immunotherapy in other autoimmune disease: multiple sclerosis. Materials & methods: Phosphatidylserine-rich liposomes were loaded with disease-specific autoantigen. Therapeutic capability of liposomes was assessed in vitro and in vivo. Results: Liposomes induced a tolerogenic phenotype in dendritic cells, and arrested autoimmunity, thus decreasing the incidence, delaying the onset and reducing the severity of experimental disease, correlating with an increase in a probably regulatory CD25+ FoxP3- CD4+ T-cell subset. Conclusion: This is the first work that confirms phosphatidylserine-liposomes as a powerful tool to arrest multiple sclerosis, demonstrating its relevance for clinical application.

Cite

CITATION STYLE

APA

Pujol-Autonell, I., Mansilla, M. J., Rodriguez-Fernandez, S., Cano-Sarabia, M., Navarro-Barriuso, J., Ampudia, R. M., … Vives-Pi, M. (2017). Liposome-based immunotherapy against autoimmune diseases: Therapeutic effect on multiple sclerosis. Nanomedicine, 12(11), 1231–1242. https://doi.org/10.2217/nnm-2016-0410

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free